Ultimovacs As

ultimovacs is a biotech company developing novel immunotherapies against cancer. the lead product candidate is uv1, a peptide-based vaccine inducing a specific t cell response against the nearly universal cancer antigen telomerase, investigated in five randomized phase 2 trials. uv1 is being developed as a therapeutic cancer vaccine for use in combination with other immuno-oncology drugs, which require an ongoing t cell response for their mode of action. ultimovacs is performing a broad clinical development program with clinical trials in europe, australia, and the usa; five phase ii trials enrolling more than 670 patients at 100 clinics in 15 countries in melanoma, mesothelioma, head & neck cancer, ovarian cancer, and non-small cell lung cancer. ultimovacs was established in 2011. the company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the oslo university hospital. the company is publicly listed at euronext oslo (ul